Another comment on cardiovascular safety of febuxostat
10.3760/cma.j.cn114015-20190830-00716
- VernacularTitle:也谈非布司他的心血管安全性
- Author:
Yu WANG
1
;
Yifan XIE
1
;
Zhuoli ZHANG
1
Author Information
1. 北京大学第一医院风湿免疫科 100034
- Publication Type:Journal Article
- Keywords:
Gout;
Cardiotoxicity;
Drug-related side effects and adverse reactions;
Febuxostat
- From:
Adverse Drug Reactions Journal
2020;22(8):445-449
- CountryChina
- Language:Chinese
-
Abstract:
Febuxostat, a new selective xanthine oxidase inhibitor, is approved by the U.S. Food and Drug Administration in 2009 for the treatment of gout and hyperuricemia. The study on the "cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES)", which was published in 2018, showed that febuxostat could increase the risk of all-cause mortality and cardiovascular related death in gout patients with cardiovascular disease. However, the subsequent clinical studies have not confirmed that febuxostat could increase the risk of cardiovascular events-related death. The inconsistent results of the studies on cardiovascular safety of febuxostat suggest that the gout patients with cardiovascular disease may benefit from continuous uric acid lowering therapy. However, during the process of using febuxostat, the risk of cardiovascular events and cardiovascular events-related death should be alerted, the combination medication and renal function of patients should be paid attention to, and the xanthine oxidase inhibitor withdrawal syndrome should be prevented.
